Cargando…

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan

BACKGROUND AND AIM: Ustekinumab, a human anti‐interleukin‐12/23 monoclonal antibody, has been approved in Japan for the treatment of Crohn's disease. Here, we report the findings from an 8‐week interim analysis of post‐marketing surveillance to evaluate the safety and effectiveness of ustekinum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokoyama, Seiji, Asano, Teita, Nagano, Katsumasa, Tsuchiya, Hiroaki, Takagishi, Masayuki, Tsujioka, Shigeharu, Miura, Naomi, Matsumoto, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Gastroenterology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290907/ https://www.ncbi.nlm.nih.gov/pubmed/34180096 http://dx.doi.org/10.1111/jgh.15600

Ejemplares similares

Safety and Effectiveness of Ustekinumab for Crohn’s Disease in Japanese Post-marketing Surveillance in Biologic-Naive and -Experienced Conriemed
por: Nagano, Katsumasa, et al.
Publicado: (2023)

Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
por: Nakamura, Shiro, et al.
Publicado: (2022)

Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
por: Gara, Sirisha K, et al.
Publicado: (2023)

Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2022)

Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study
por: Thomas, Pepijn W.A., et al.
Publicado: (2022)

Long‐term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease
por: Shiga, Hisashi, et al.
Publicado: (2022)

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
por: af Björkesten, Clas-Göran, et al.
Publicado: (2020)

Hepatocellular Carcinoma in a Patient With Crohn’s Disease
por: Hokama, Akira, et al.
Publicado: (2021)

The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
por: Kapila, Nikhil, et al.
Publicado: (2018)

An Unusual Presentation of Crohn’s Disease and Primary Sclerosing Cholangitis
por: Ekanayake, Lakmal S, et al.
Publicado: (2022)

Acute Intestinal Invagination: An Exceptional Method of Revealing Crohn’s Disease
por: Jabi, Rachid, et al.
Publicado: (2021)

Macroscopic to Microscopic – A Case of Crohn’s Disease Progressing to Collagenous Colitis
por: Hussain, Murtaza Shabbir, et al.
Publicado: (2021)

Wernicke’s Encephalopathy in a Patient With Crohn’s Disease: A Case Report
por: Adamou, Fatima, et al.
Publicado: (2023)

A Challenging Case of Metastatic Crohn's Disease Without Gastrointestinal Manifestations
por: Pereira, Ana S, et al.
Publicado: (2023)

High Adenoma Detection Rates in Fecal Immunochemical Test-Based Colorectal Cancer Screening: Interim Results of the National Bowel Cancer Screening Program in Qatar
por: John, Anil K, et al.
Publicado: (2022)

Meckel’s Diverticulum Charading as Crohn’s Disease: A Single-Institution Case Series
por: Eng, Nina L, et al.
Publicado: (2023)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Helicobacter pylori is Associated with Less Fistulizing, Stricturing, and Active Colitis in Crohn’s Disease Patients
por: Fialho, Andre, et al.
Publicado: (2019)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Identifying Visceral Kaposi Sarcoma (KS): A Responsibility to Avoid Anchoring on the Diagnosis of a Crohn’s Flare
por: Seltzer, Emily S, et al.
Publicado: (2023)

Atypical Clinical Presentation of Crohn’s Disease as Diffuse Abdominal Lymphadenopathy and Venous Thrombosis: A Difficult to Diagnose Case
por: Raza, Ahmad, et al.
Publicado: (2019)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Clinical and Histologic Remission in an Adult Crohn’s Disease Patient Following the Specific Carbohydrate Diet and Its Impact on Healthcare Costs
por: Arjomand, Ali, et al.
Publicado: (2022)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn’s disease or ulcerative colitis
por: Gheorghe, Cristian, et al.
Publicado: (2019)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
por: Hirayama, Hisashi, et al.
Publicado: (2022)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab
por: Lim, Yizhe, et al.
Publicado: (2021)

Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn’s Disease: A Case Report and Review of the Literature
por: Matsumoto, Satohiro, et al.
Publicado: (2020)

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study
por: Paulides, Emma, et al.
Publicado: (2022)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease
por: Cohen, Barrie, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn's Disease
por: Andres, Brendan, et al.
Publicado: (2022)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
por: Xiao, Teresa L., et al.
Publicado: (2022)

Acupuncture for Crohn’s disease: a protocol for systematic review and meta-analysis
por: Han, Qiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_32vns277gi5m5v9gslsouf2vt1